Roxudo (Roxadustat) – 100 mg Tablets

Description

Roxudo, manufactured by CCL Pharmaceuticals as shown in “118.webp”, utilizes the active ingredient Roxadustat to treat chronic kidney disease-induced anemia in both dialysis and non-dialysis patients. Rather than introducing external synthetic hormones into the body, Roxudo triggers a natural biological response. By selectively blocking the prolyl hydroxylase enzyme, it stabilizes the HIF complex, mimicking a low-oxygen environment. This signals the body to safely upregulate its internal erythropoietin production while simultaneously maximizing gastrointestinal iron absorption and transport pathways to build healthy hemoglobin levels.

Advanced Dosing Structure The 100 mg formulation serves as a high-strength option within the clinical titration hierarchy, giving nephrologists and hematologists the ability to design intensive maintenance regimens or correct severe hemoglobin deficits efficiently. Packaged as a clean, convenient layout of 12 tablets, it dramatically simplifies therapy by offering a patient-friendly oral alternative to traditional, complex injection schedules. Developed under strict regulatory standards by CCL, Roxudo 100 mg delivers reliable, systemic support to improve vitality and physical endurance in chronic renal patients.